XELJANZ Trademark

Trademark Overview

On Wednesday, March 11, 2009, a trademark application was filed for XELJANZ with the United States Patent and Trademark Office. The USPTO has given the XELJANZ trademark a serial number of 77688128. The federal status of this trademark filing is REGISTERED AND RENEWED as of Tuesday, June 29, 2021. This trademark is owned by Pfizer Inc.. The XELJANZ trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the treatment of immunological and inflammatory diseases and disorders; pharmaceutical preparations for the treatment of pain; pharmaceutical preparations, namely, dermatological preparations
xeljanz

General Information

Serial Number77688128
Word MarkXELJANZ
Filing DateWednesday, March 11, 2009
Status800 - REGISTERED AND RENEWED
Status DateTuesday, June 29, 2021
Registration Number4099367
Registration DateTuesday, February 14, 2012
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, June 23, 2009

Trademark Statements

Goods and ServicesPharmaceutical preparations for the treatment of immunological and inflammatory diseases and disorders; pharmaceutical preparations for the treatment of pain; pharmaceutical preparations, namely, dermatological preparations

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, March 16, 2009
Primary Code005
First Use Anywhere DateThursday, October 20, 2011
First Use In Commerce DateThursday, October 20, 2011

Trademark Owner History

Party NamePfizer Inc.
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressNew York, NY 100012192
Party NamePfizer Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressNew York, NY 10017
Party NamePfizer Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNew York, NY 10017

Trademark Events

Event DateEvent Description
Thursday, April 6, 2023APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Thursday, April 6, 2023TEAS CHANGE OF CORRESPONDENCE RECEIVED
Thursday, April 6, 2023ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Thursday, April 6, 2023TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Thursday, April 6, 2023TEAS CHANGE OF OWNER ADDRESS RECEIVED
Tuesday, June 29, 2021NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED
Tuesday, June 29, 2021REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS)
Tuesday, June 29, 2021REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED
Tuesday, June 29, 2021CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Tuesday, March 23, 2021TEAS SECTION 8 & 9 RECEIVED
Thursday, February 25, 2021APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Thursday, February 25, 2021TEAS CHANGE OF CORRESPONDENCE RECEIVED
Thursday, February 25, 2021TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Thursday, February 25, 2021ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Thursday, February 25, 2021TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Thursday, February 25, 2021TEAS CHANGE OF OWNER ADDRESS RECEIVED
Sunday, February 14, 2021COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
Saturday, February 3, 2018NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
Saturday, February 3, 2018REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
Saturday, February 3, 2018CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Wednesday, January 17, 2018TEAS SECTION 8 & 15 RECEIVED
Tuesday, February 14, 2017COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Tuesday, February 14, 2012REGISTERED-PRINCIPAL REGISTER
Wednesday, January 11, 2012NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Tuesday, January 10, 2012LAW OFFICE REGISTRATION REVIEW COMPLETED
Tuesday, January 10, 2012ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Wednesday, January 4, 2012STATEMENT OF USE PROCESSING COMPLETE
Thursday, December 15, 2011USE AMENDMENT FILED
Thursday, December 15, 2011TEAS STATEMENT OF USE RECEIVED
Thursday, September 22, 2011NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, September 21, 2011SOU EXTENSION 4 GRANTED
Thursday, September 15, 2011SOU EXTENSION 4 FILED
Thursday, September 15, 2011TEAS EXTENSION RECEIVED
Tuesday, March 8, 2011NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Saturday, March 5, 2011SOU EXTENSION 3 GRANTED
Wednesday, March 2, 2011SOU EXTENSION 3 FILED
Wednesday, March 2, 2011TEAS EXTENSION RECEIVED
Thursday, October 7, 2010NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, October 6, 2010NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, October 5, 2010SOU EXTENSION 2 GRANTED
Monday, September 13, 2010SOU EXTENSION 2 FILED
Tuesday, October 5, 2010CASE ASSIGNED TO INTENT TO USE PARALEGAL
Monday, September 13, 2010TEAS EXTENSION RECEIVED
Friday, September 10, 2010ASSIGNED TO EXAMINER
Monday, March 8, 2010SOU EXTENSION 1 GRANTED
Monday, March 8, 2010SOU EXTENSION 1 FILED
Monday, March 8, 2010TEAS EXTENSION RECEIVED
Tuesday, September 15, 2009NOA MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, June 23, 2009PUBLISHED FOR OPPOSITION
Wednesday, June 3, 2009NOTICE OF PUBLICATION
Thursday, May 21, 2009LAW OFFICE PUBLICATION REVIEW COMPLETED
Thursday, May 21, 2009ASSIGNED TO LIE
Thursday, May 21, 2009APPROVED FOR PUB - PRINCIPAL REGISTER
Monday, May 11, 2009ASSIGNED TO EXAMINER
Monday, March 16, 2009NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Saturday, March 14, 2009NEW APPLICATION ENTERED

Related Keywords

xeljanz preparations pharmaceutical treatment namely pain dermatological inflammatory immunological diseases disorders